Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | DMPK | Q09013 | 1/20 | 0.33 |
| ▸ | MYLK | Q15746 | 1/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353896 | 0.86 | KMT2A (0.37) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL19119126 | 0.86 | LMNA (0.36) | ROCK1LMNAP2RX7ROCK2MAPT | |
| SCHEMBL352836 | 0.84 | ROCK2 (0.51) | ROCK1ROCK2SGK1AKT1GSK3B | |
| SCHEMBL352830 | 0.84 | SHMT2 (0.36) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL352380 | 0.82 | ROCK1 (0.39) | ROCK1LMNAROCK2SGK1AKT1 | |
| SCHEMBL354220 | 0.81 | ROCK1 (0.38) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL19119542 | 0.77 | ROCK1 (0.40) | ROCK1LMNAROCK2SGK1AKT1 | |
| SCHEMBL19119206 | 0.76 | LMNA (0.38) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL19118751 | 0.75 | LMNA (0.36) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL2068257 | 0.75 | ROCK1 (0.47) | ROCK1LMNAROCK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | ROCK1 4747/4885LMNA 4293/4885P2RX7 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.